A0532 - Ongoing phase II study of EZH2 inhibitor CPI-0209 in patients with advanced solid tumors including metastatic castration-resistant prostate cancer (mCRPC) or hematologic malignancies

Kwiatek, M. ; Gutierrez, M. ; Harvey, R.D. ; Sullivan, R.J. ; Walter, H.S. ; Faulhaber, N. ; Jauch-Lembach, J. ; Kann, L. ; Lakhani, N.J.

European urology, 2023-02, Vol.83, p.S758-S759 [Periódico revisado por pares]

Elsevier B.V

Texto completo disponível